PLX Pharma Inc (fka PLXPQ)

[make it happen]

$0.00 revenue per share

Profitability on operating -50,346.88%!!! Have never seen such a high negative percentage in my life

Losing huge double digits on returns

Negative -$20,000,000 cash flow

[make it happen]

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -50,346.88%

Management Effectiveness
Return on Assets (ttm) -17.22%
Return on Equity (ttm) -76.80%

Income Statement
Revenue (ttm) 27.91k
Revenue Per Share (ttm) 0.00
Gross Profit (ttm) 30.43k
EBITDA -13.93M
Net Income Avi to Common (ttm) -29.51M
Diluted EPS (ttm) -2.57

Cash Flow Statement
Operating Cash Flow (ttm) -12.75M
Levered Free Cash Flow (ttm) -7.54M

[make it happen]

10x market cap since last year due to dilution.

Current Market Cap (intraday) 295.31M
3/31/2021 206.21M
12/31/2020 76.79M
9/30/2020 29.57M
6/30/2020 29.67M

[conix]

PLXP Chart

[otcmoneydoubler]

PLXP ASK THIN TO $50

[conix]

PLx Pharma: Building a Better Aspirin

PLx Pharma Inc. (NASDAQ: PLXP) is going to be rather risky due to its market value of just $63 million. Last seen at $7.20, the shares have a 52-week range of $5.60 to $12.80, and the stock is classified as low volume by traders. PLx Pharma is focused on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents, and its lead product is Aspertec (325 mg) as a better formulation of aspirin that seeks to reduce acute gastrointestinal side effects while still providing antiplatelet effectiveness for cardiovascular disease prevention. In short, it’s looking to build a better aspirin.

PLx is preparing to launch its better aspirin under the Aspertec name in 2019. This is an alternative to enteric-coated aspirin that is used by about 90% of patients. Janney recently initiated coverage with an Outperform rating and a $14 fair value for PLx. The firm believes that Aspertec’s differentiation exceeds that of other over-the-counter consumer health care products (Airborne, MegaRed and Mucinex) that already have achieved commercial success.

Janney started the stock as Buy with a $14 fair value estimate (versus a $6.10 prior close). The firm noted that PLx is creating a branded over-the-counter health care franchise with a better aspirin for use as an antiplatelet agent. Janney’s report sees Aspertec sales hitting $100 million to $200 million, but it also thinks sales can reach $300 million or more:

After establishing Aspertec as the brand of choice among such specialists in the first few years of launch, PLx plans to implement a direct-to-consumer ad campaign to make the 50 million people taking aspirin aware of Aspertec. … We have confidence sales of Aspertec can reach $100-$200 million and may peak well in excess of $300 million. Considering existing independent OTC consumer healthcare companies trade in the range of 4X-6X sales, it suggests PLx has long-term potential that is far greater than its present $60 million market cap. Even after factoring in significant dilution that will result from raising capital needed to launch Aspertec and applying a 30% discount rate, we arrive at a fair value range of $10-$18 per share.

[theStockGAMEoOo]

Looking promising IMO. I've been watching since the $5.80 levels. The combined experience of the new team members that have been added to management here is intriguing.

[wildred1]

not sure on this one , any hope of a comeback?

[Hawkeye_tt]

In connection with the completion of the merger, Dipexium effected a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-8. The holders of shares of PLx common stock outstanding immediately prior to the merger received, as merger consideration, shares of common stock in the combined company representing 76.75% of the outstanding shares of the combined company. Immediately following the merger, there were 6,037,824 shares of common stock of the combined company outstanding.

The combined company will continue to operate under the leadership of the PLx management team with Michael Valentino serving as Executive Chairman of the Board of Directors and Natasha Giordano serving as President and Chief Executive Officer.

[Cheesesteak_Lover]

Okay, let's see what happens. All I want is to make some money, just like everyone else.

[TTT]

PLx Pharma merges with Dipexium Pharmaceuticals

Late-stage specialty pharmaceutical company PLx Pharma has completed its previously announced merger with Dipexium Pharmaceuticals.

The combined company, also known as PLx Pharma, will focus on commercialising two patent-protected products, namely, 325mg of Aspertec and 81mg of Aspertec (jointly referred to as Aspertec).

PLx president and chief executive officer Natasha Giordano said: “With the successful completion of this merger, we have strengthened the foundation of PLx and are now well positioned to advance our development efforts for Aspertec and prepare for commercialisation of this important cardiovascular product.”

With the merger now complete, PLx Pharma will complete the manufacturing scale-up and label finalisation for its FDA-approved 325mg of Aspertec aspirin dosage form.

The company will also submit a supplemental new drug application (sNDA) for an 81mg of Aspertec maintenance dose form.
"The company will also submit a supplemental new drug application (sNDA) for an 81mg of Aspertec maintenance dose form."

Aspertec is designed to provide reliable and predictable antiplatelet efficacy to high-risk cardiovascular and stroke patients compared to enteric coated aspirin.

Under this merger, Dipexium carried out a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-8.

PLx shareholders received shares of common stock in the combined company representing 76.75% of the outstanding shares of the combined company as merger consideration.

There were 6.3 million shares of the combined company's outstanding common stock immediately following the merger.

The combined company will continue to be led by the PLx management team.

Michael Valentino will assume the role of executive chairman of the board of directors, while Natasha Giordano will serve as president and chief executive officer of the merged entity.

[Diggie-HH]

What kind of NEWS? Is it a Reverse Split? or what=?

My Account shows almost 10 Dollar, per share, yesterday 1,3 Dollar per share

[TTT]

The news is above.